drugset / Trial / NCT00722475

Trial of the Efficacy of Intravenous Immunoglobulin for Treating Women With Unexplained Secondary Recurrent Miscarriage

NCT00722475

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The investigators want to test whether infusions of intravenous immunoglobulin - a blood product known to modify immune responses - in early pregnancy will increase the chance of a subsequent live birth in women with three or more miscarriages after a birth and a total of at least four miscarriages. This will be done in a trial where 82 patients will be randomly allocated to infusions with intravenous immunoglobulin or placebo during pregnancy.

Timeline

Start
2008-08
Primary completion
2014-05
Completion
2014-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 25 g Intravenous
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 35 g Intravenous